These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32616655)

  • 1. Selected Articles from This Issue.
    Mol Cancer Ther; 2020 Jul; 19(7):1383. PubMed ID: 32616655
    [No Abstract]   [Full Text] [Related]  

  • 2. Selected Articles from This Issue.
    Clin Cancer Res; 2020 May; 26(10):2279. PubMed ID: 32414759
    [No Abstract]   [Full Text] [Related]  

  • 3. Paul Workman: Drugging the Cancer Genome.
    Trends Cancer; 2016 Oct; 2(10):544-548. PubMed ID: 27904887
    [No Abstract]   [Full Text] [Related]  

  • 4. MKK3 as oncotarget.
    Bossi G
    Aging (Albany NY); 2016 Jan; 8(1):1-2. PubMed ID: 26805700
    [No Abstract]   [Full Text] [Related]  

  • 5. Special issue: Current vision on target enzymes for cancer therapy.
    Bishayee A; Kamal MA
    Semin Cancer Biol; 2019 Jun; 56():iii-v. PubMed ID: 30503852
    [No Abstract]   [Full Text] [Related]  

  • 6. Is Precision Medicine an Oxymoron?
    Eckhardt SG; Lieu C
    JAMA Oncol; 2019 Feb; 5(2):142-143. PubMed ID: 30419105
    [No Abstract]   [Full Text] [Related]  

  • 7. New ESMO scale ranks mutations as cancer medicine targets.
    Fricker J
    Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
    [No Abstract]   [Full Text] [Related]  

  • 8. Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies.
    Bruinooge SS; Sherwood S; Grubbs S; Schilsky RL
    J Oncol Pract; 2019 Nov; 15(11):575-583. PubMed ID: 31386607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial (Thematic Issue: The Predictive Pathology in the Target Therapy Era).
    Franco R; Cantile M
    Curr Drug Targets; 2017; 18(1):2-3. PubMed ID: 27991404
    [No Abstract]   [Full Text] [Related]  

  • 10. Maurie Markman on the Groundbreaking TAPUR Trial.
    Markman M
    Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
    [No Abstract]   [Full Text] [Related]  

  • 11. Precision Medicine.
    Khatri VP; Petrelli NJ
    Surg Oncol Clin N Am; 2020 Jan; 29(1):xv-xvi. PubMed ID: 31757318
    [No Abstract]   [Full Text] [Related]  

  • 12. Understanding the Cause and Consequence of Tumor Heterogeneity.
    Khatib S; Pomyen Y; Dang H; Wang XW
    Trends Cancer; 2020 Apr; 6(4):267-271. PubMed ID: 32209440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.
    Italiano A
    Pharmacol Ther; 2016 Sep; 165():26-31. PubMed ID: 27179746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.
    Hansen AR; Siu LL
    JAMA Oncol; 2016 Jan; 2(1):15-6. PubMed ID: 26562503
    [No Abstract]   [Full Text] [Related]  

  • 15. Selected Articles from This Issue.
    Clin Cancer Res; 2020 Apr; 26(8):1779. PubMed ID: 32295813
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular pathology in therapeutics: where are we now, and where are we going?
    Harrison DJ; Faratian D
    Curr Drug Targets; 2012 Nov; 13(12):1473-4. PubMed ID: 22974390
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
    Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
    Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments on targeted cancer therapy: Multi-faceted issues in targeted cancer therapy.
    Bao J; Qiao L
    Cancer Lett; 2017 Feb; 387():1-2. PubMed ID: 28038727
    [No Abstract]   [Full Text] [Related]  

  • 19. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
    Marquart J; Chen EY; Prasad V
    JAMA Oncol; 2018 Aug; 4(8):1093-1098. PubMed ID: 29710180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics.
    Comment LA; Ward AF; Schrock AB; Fabrizio D; Venstrom JM; Hegde PS; Alexander BM
    Clin Pharmacol Ther; 2020 Sep; 108(3):440-443. PubMed ID: 32744335
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.